Bioanalytical Research Services for Drug Development

Immunology & Inflammation

Autoimmune diseases are chronic conditions where the immune system attacks the body’s own tissues or organs, leading to significant clinical conditions. While traditional treatments focus on immune suppression, new therapies are emerging to modify or regulate the immune response. When developing these new therapies, it is imperative that sponsors partner with a CRO that has significant bioanalytical and clinical expertise in this complex space. 

Learn more about why BioAgilytix is the CRO partner of choice for the highest quality results in immunology and Inflammation.

Neurology

Neurologic disorders, including Alzheimer’s Disease and Multiple Sclerosis (MS), are on the rise in industrialized countries. Treatments for neurologic disorders are difficult to develop due to limited understanding of their causes. Companies developing neurology-related drugs need a CRO partner well-versed in the complexities of therapies targeting neurological diseases throughout all phases of development.

Learn more about BioAgilytix’s expertise in bioanalysis for neurological disorders.

Infectious Disease

BioAgilytix has extensive infectious disease expertise, with decades of bioanalytical support for antiviral drug discovery and development. With experience in cell culture-based virology, immunology, and molecular biology, BioAgilytix is well-equipped to support the successful development of vaccines and therapies.

Rare and Orphan Diseases

Global health agencies identify a “rare disease” as a condition which affects a small population of individuals and a therapeutic that is intended to treat such a disease as an “orphan drug.” Although the incidence rates used to define rare diseases vary by country, working with rare diseases is universally challenging due to small patient populations and difficulty enrolling enough individuals in clinical programs. Having a strong bioanalytical partner that is well versed in working with rare or difficult to obtain disease matrices can be critical.

Oncology

Every year, an estimated two million people are diagnosed with some form of cancer. While mortality rates continue to decline, there is an ongoing need for improved oncology treatments.

Promising new therapies are shifting the cancer landscape and offering new alternatives to traditional options like surgery, chemotherapy, and radiotherapy. Antibody drug conjugates (ADCs) and immuno-oncological approaches target tumors while sparing healthy tissue, offering new potential for curative treatment. These molecular and personalized methods may lead to a new era in cancer therapy, but having a CRO with a track record in complex therapeutics is essential to fully realize their potential.

Cardiovascular Disease

According to the World Health Organization, 32% of global deaths in 2019 were a result of cardiovascular diseases (CVDs). CVDs are a group of diseases that impact the function of heart and blood tissues. Targeted therapeutics for a variety of CVDs have attained marketing approval from global regulatory bodies, but a multitude of drugs for this therapeutic area are still in preclinical and clinical testing stages. BioAgilytix has supported clients with many different therapeutic strategies for CVDs from protein-based to nucleic acid-based drugs. By leveraging our knowledge with CVD drug programs, we can streamline future bioanalytical projects in this field. 

Metabolic Disease

The global market for metabolic disease therapeutics is expected to grow steadily due to the increasing prevalence of these types of medical conditions. Advances in understanding patient genetics allow for more precise targeting of enzyme deficiencies, with gene therapy showing promise for inherited metabolic diseases. To conduct complex large molecule studies effectively, pharmaceutical and biotechnology companies need a reliable CRO partner with expertise in endocrine disorders and metabolic diseases, that also has proven experience in assessing the impact of large molecule drug candidates on body functions.

Animal Health

Therapeutics for veterinary use are a growing area for both companion and livestock animal health. As with human health, innovative veterinary treatments are tested in preclinical studies and veterinary clinical trials prior to market approval. These therapeutics range across a variety of indications including oncology, autoimmune disease, and metabolic disease. Each species has unique challenges and considerations when it comes to building bioanalytical assays. Sourcing matrices and specific reagents can be difficult and understanding the distinct biology for each animal system is critical. At BioAgilytix, we have a long history of supporting animal health companies and working with therapeutics for a variety of companion and livestock animal species.